Immunology Clinical Trials Update: Week 23, 2026

Published June 5, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

This Phase 2 study is exploring the use of biologic drugs combined with oral immunotherapy for people with multiple food allergies, including peanut allergy. By enrolling 130 participants aged 4 to 55 across several US sites, the trial aims to find a treatment that not only improves allergy outcomes but also enhances safety for patients managing several food allergies at once. If successful, this approach could provide a new option to reduce allergic reactions and improve daily life for those with complex food allergies.

A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65

This Phase 3 trial is testing a sublingual immunotherapy tablet designed to treat house dust mite allergy in Chinese patients between the ages of 12 and 65. The treatment involves placing a tablet under the tongue to help reduce allergy symptoms such as sneezing, runny nose, and itchy eyes. If effective, this could offer a convenient and non-invasive way to manage allergic rhinitis, improving daily comfort and quality of life for many sufferers.

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

This Phase 2 trial is investigating a new cell therapy called rapcabtagene autoleucel for adults with active, refractory systemic lupus erythematosus or lupus nephritis who have not responded to existing treatments. The therapy aims to better control disease activity and reduce symptoms, potentially offering relief and improved quality of life for patients facing difficult-to-treat lupus. The study is currently recruiting participants worldwide.

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

This Phase 3 trial is evaluating the safety and effectiveness of a 10% intravenous immunoglobulin treatment in children with primary immunodeficiency disease. This condition makes it harder for children to fight infections, so a reliable treatment like this could help strengthen their immune system and reduce illness. The study involves about 30 children across multiple countries and is active but not recruiting new participants.

Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

This Phase 2 study is testing a new injection called Stapokibart for adolescents with seasonal allergic rhinitis, commonly known as hay fever. The trial is looking at how safe the treatment is and how it works in the body, which could lead to a new option for managing allergy symptoms like sneezing and nasal congestion during allergy season. Recruitment is ongoing in China for this small study.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.